Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711251 | 0.89 | HTT (0.34) | HTTKMT2ALMNAGALR3RAB9A | |
| SCHEMBL4018016 | 0.86 | PTGES (0.37) | HTTKMT2ALMNAPTGES | |
| SCHEMBL4711254 | 0.84 | KMT2A (0.35) | KMT2ATBXAS1CA1CA2 | |
| SCHEMBL4017082 | 0.82 | SERPINE1 (0.40) | KMT2ALMNASMN1; SMN2PTGES | |
| SCHEMBL4019018 | 0.74 | TDP1 (0.46) | HTTKMT2ALMNASMN1; SMN2TDP1 | |
| SCHEMBL4022508 | 0.73 | CA1 (0.45) | HTTKMT2ASMN1; SMN2CA1CA2 | |
| SCHEMBL4022515 | 0.73 | CA1 (0.45) | CA1CA2 | |
| SCHEMBL4714206 | 0.72 | CA1 (0.44) | HTTKMT2ASMN1; SMN2CA1CA2 | |
| SCHEMBL23895473 | 0.72 | POLB (0.42) | HTTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL4021417 | 0.70 | LIMK2 (0.39) | HTTKMT2ALMNASMN1; SMN2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | claimed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
| WO-2007093557-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRES SERONO S.A. (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | HTT 4318/4885KMT2A 2981/4885TBXAS1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.